ALK and non-small cell lung carcinoma: In association with SMARCA4 mutations and clinico-genomic biomarkers across two different studies, tumor mutational burden (TMB) and brain metastasis in Anaplastic Lymphoma Kinase (ALK)-positive NSCLC were evaluated [24,25].